abstract |
The invention concerns phenoxypropanolamines of formula (I) wherein: R 1 represents a hydrogen, a —S(O) z —(C 1 -C 4 )Alk-R′ group, R′ being H, phenyl or (C 1 -C 4 ) alkoxy), —NHSO 2 —(C 1 -C 4 ) Alk, NHCO(C 1 -C 4 ) Alk; m and n are each independently 0, 1 or 2; R 2 and R 3 represent independently a hydrogen, a (C 5 -C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl, (C 1 -C 4 ) alkoxy, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 ) alkoxy-(C 1 -C 4 )alkyl, mono-or di-(C 1 -C 4 )Alk-amino(C 1 -C 4 )alkyl, pyrrolidino-(C 1 -C 4 )alkyl, phenylamino, (C 2 -C 4 )alkenyl group, or an aromatic or heteroaromatic group substituted or not with a group R 4 ; R 2 and R 3 can also together constitute a saturated or unsaturated cycle of 3 to 6 atoms capable of bearing a (C 1 -C 4 ) alkyl, amino(C 1 -C 4 )alkyl, carbamoyl or benzyl substituent; R 4 represents a hydrogen or a halogen, a —CO(C 1 -C 4 )Alk group or a —NHSO 2 —(C 1 -C 4 )Alk group; a (C 1 -C 4 )Alk group, a (C 1 -C 4 )alkoxy group, a halogen, —COOH, —COO(C 1 -C 4 )Alk, —CN, —CONR 3 R 4 , —NO 2 , —SO 2 NH 2 , —NHSO 2 (C 1 -C 4 )Alk; z is 1 or 2; and their salts and solvates. Said compounds have an agonist activity with respect to β-3 adrenergic receptors. |